| Literature DB >> 34448038 |
Stefano Angioni1, Luigi Nappi2, Felice Sorrentino2, Michele Peiretti3, Angelos Daniilidis4, Alessandro Pontis5, Raffaele Tinelli6, Maurizio Nicola D'Alterio3.
Abstract
PURPOSE: To evaluate whether laparoscopic treatment with a diode laser is feasible, safe, and effective in symptomatic patients affected by deep endometriosis (DE).Entities:
Keywords: Deep endometriosis; Diode laser; Endometriosis; Pelvic pain; Quality of life; Surgical treatment
Mesh:
Year: 2021 PMID: 34448038 PMCID: PMC8490256 DOI: 10.1007/s00404-021-06154-z
Source DB: PubMed Journal: Arch Gynecol Obstet ISSN: 0932-0067 Impact factor: 2.344
Fig. 1Leonardo DUAL 45 laser device
Preoperative characteristics of the patients
| All patients ( | |
|---|---|
| Age (years), median (interval) | 32 (21–44) |
| Body mass index, kg/m2 mean ± SD | 21.7 ± 2.9 |
| Indication for surgery, | |
| Chronic pelvic pain | 50 (100) |
| Dysmenorrhoea | 50 (100) |
| Dyspareunia | 44 (88) |
| Dyschezia | 20 (40) |
| Dysuria | 10 (20) |
| Infertility | 20 (40) |
| Prior abdominal surgery, | 30 (60) |
| Prior medical treatment, | 50 (100) |
Fig. 2Diode laser ureterolysis
Fig. 3Vaginal nodule delimitation with the diode laser by vaginal route
Fig. 4Laparoscopic excision of deep endometriosis infiltrating uterosacral ligaments
Surgical findings
| All patients ( | |
|---|---|
| Surgical procedures, | |
| Adhesiolysis | 50 (100) |
| Posterior fornix resection | 30 (60) |
| Excision of DE infiltrating uterosacral ligaments | 35 (70) |
| Ureterolysis | 40 (80) |
| Partial bladder resection | 10 (20) |
| Bowel shaving | 35 (70) |
| Full-thickness anterior rectal wall excision | 5 (10) |
| Rectosigmoid resection | 6 (12) |
| Mean operative time (min), mean (interval) | 147 (106–190) |
| Intraoperative complications, | 0 (0) |
| Conversion to laparotomy, | 0 (0) |
| Estimated blood loss, ml mean ± SD | 129.2 ± 46.8 |
| Hospital stay (days), mean (interval) | 3 (2–9) |
| Number of patients with fever > 38 °C, | 4 (8) |
| Number of patients analgesic-free at day 2, | 35 (70) |
| Hormonal therapy after surgery (dienogest 2 mg), | 30 (60) |
| Postoperative pregnancy intent, | 20 (40) |
Fig. 5Cumulative pain scores at 0, 3, 6, and 12 months (*p < 0.01 vs. baseline)
Fig. 6Differences in the patients’ quality of life, as assessed by SF36, before surgery and at 12 months follow-up (*p < 0.01 vs. baseline)